Life Sciences organisations face an extremely challenging D&O market, one that is creating significant headwinds for firms looking to coverage to support capital raising, IPOs and M&A.
This paper explores some of the reasons behind the hardening market – including recent accelerants of the trend – and suggests what life sciences organisations can do to better prepare for what will undoubtedly be some tough renewals.
Drawing on insights from our life sciences and D&O teams from across Europe and the US, it provides analysis and actionable insights into the D&O challenge facing the sector
Issues addressed in the white paper include:
- The impact of the US opioid crisis on life sciences D&O and the heightened litigation exposure this has created for the sector
- The implications of the search for a vaccine and therapeutic cures for COVID-19 on class action litigation, D&O pricing and appetite
- Renewal planning and considerations for life sciences organisations as they engage with the insurance market in the coming months
Contact our Practice Leaders:
